摘要
目的探讨厄贝沙坦、氢氯噻嗪、氨氯地平联合美托洛尔治疗难治性高血压的效果。方法选择接受治疗的80例难治性高血压患者,按照自愿原则,分为观察组和对照组各40例。对照组采用厄贝沙坦、氢氯噻嗪、氨氯地平进行治疗。观察组在对照组基础上加用美托洛尔进行治疗,疗程3个月。结果观察组显效35例,有效5例,无效0例;对照组显效27例,有效9例,无效4例。观察组的临床疗效优于对照组(P<0.05)。观察组不良反应发生率为0.00%,对照组为30.00%,观察组不良反应发生率显著低于对照组(P<0.01)。结论厄贝沙坦、氢氯噻嗪、氨氯地平联合美托洛尔可有效提高降压效果,减少不良反应发生,药物相互协同,安全可靠。
Objective To study the effects of irbesartan, hydrochlorothiazide and amlodipine combined with metopmlol in the treatment of refractory hypertension. Methods Eighty patients with refractory hypertension were divided into the observation group (n = 40) and the control group( n = 40) according to the principle of voluntary. The control group received the treatment of irbesartan, hydrochlorothiazide and amlodipine. The treatment in the observation group was tile same as that in the control group except that metoprolol was added. Results In the observation group, 35 cases were markedly effective; 5 cases effective; No cases ineffective. In the control group, 27 cases were effective ; 9 cases effective; 4 cases ineffective. The clinical effect of the observation group was better than that of the control group(P 〈0.05 ). The incidence of adverse reactions in the observation group(0. 00% ) was significantly lower than that in the control group(30. 00% ) (P 〈 0.01 ). Conclusion Irbesartan in conjunction with hydrogen chlorine thiophene hydrochlorothiazide and amlodipine combined with metoprolol is safe and effective in the treatment of refractory hypertension.
出处
《中国临床新医学》
2016年第4期307-309,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE